Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line

被引:13
|
作者
Kang, Chung Hyo [1 ,2 ]
Kim, Yeongrin [1 ,3 ]
Lee, Heung Kyoung [1 ]
Lee, So Myoung [1 ]
Jeong, Hye Gwang [2 ]
Choi, Sang Un [1 ]
Park, Chi Hoon [1 ,3 ]
机构
[1] Korea Res Inst Chem Technol, Therapeut & Biotechnol Div, POB 107, Daejeon 34114, South Korea
[2] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
[3] Korea Univ Sci & Technol, Med Chem & Pharmacol, Daejeon 34113, South Korea
关键词
CD19; chimeric-antigen receptor; scFv; FMC63; leukemia;
D O I
10.3390/ijms21239163
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial. Most of these anti-CD19 CAR T cells use FMC63 single-chain variable fragments (scFvs) for binding CD19 expressed on the cancer cell surface. In this study, we screened several known CD19 scFvs for developing anti-CD19 CAR T cells. We used the KHYG-1 NK/T-cell line for screening of CD19 scFvs because it has advantages in terms of cell culture and gene transduction compared to primary T cells. Using our CAR construct backbone, we made anti-CD19 CAR constructs which each had CD19 scFvs including FMC63, B43, 25C1, BLY3, 4G7, HD37, HB12a, and HB12b, then made each anti-CD19 CAR KHYG-1 cells. Interestingly, only FMC63 CAR KHYG-1 and 4G7 CAR KHYG-1 efficiently lysed CD19-positive cell lines. In addition, in Jurkat cell line, only these two CAR Jurkat cell lines secreted IL-2 when co-cultured with CD19-positive cell line, NALM-6. Based on these results, we made FMC63 CAR T cells and 4G7 CAR T cells from PBMC. In in vitro lysis assay, 4G7 CAR T cells lysed CD19-positive cell line as well as FMC63 CAR T cells. In in vivo assay with NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice, 4G7 CAR T cells eradicated NALM-6 as potently as FMC63 CAR T cells. Therefore, we anticipate that 4G7 CAR T cells will show as good a result as FMC63 CAR T cells for B-cell leukemia patients.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [21] CAR assembly line: Taking CAR T-cell manufacturing to the next level
    Wang, Jiasheng
    Caimi, Paolo F.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2024, 37 (04)
  • [22] CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas
    Onea, Alexandra S.
    Jazirehi, Ali R.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (02): : 403 - 424
  • [23] CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL
    Epperly, Rebecca
    Shulkin, Barry L.
    Bag, Asim K.
    Cheng, Cheng
    Inaba, Hiroto
    Lucas, John T., Jr.
    Naik, Swati
    Triplett, Brandon M.
    Gottschalk, Stephen
    Talleur, Aimee C.
    BLOOD ADVANCES, 2023, 7 (20) : 6320 - 6324
  • [24] Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma
    Yan, Lingzhi
    Qu, Su
    Shang, Jingjing
    Shi, Xiaolan
    Kang, Liqing
    Xu, Nan
    Zhu, Mingqing
    Zhou, Jin
    Jin, Song
    Yao, Weiqin
    Yao, Ying
    Chen, Guanghua
    Chang, Huirong
    Zhu, Xiaming
    Yu, Lei
    Wu, Depei
    Fu, Chengcheng
    CANCER MEDICINE, 2021, 10 (02): : 563 - 574
  • [25] Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming
    Simonetta, Federico
    Lohmeyer, Juliane K.
    Hirai, Toshihito
    Maas-Bauer, Kristina
    Alvarez, Maite
    Wenokur, Arielle S.
    Baker, Jeanette
    Aalipour, Amin
    Ji, Xuhuai
    Haile, Samuel
    Mackall, Crystal L.
    Negrin, Robert S.
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 6054 - 6064
  • [26] A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells
    Reusch, Uwe
    Duell, Johannes
    Ellwanger, Kristina
    Herbrecht, Carmen
    Knackmuss, Stefan H. J.
    Fucek, Ivica
    Eser, Markus
    McAleese, Fionnuala
    Molkenthin, Vera
    Le Gall, Fabrice
    Topp, Max
    Little, Melvyn
    Zhukovsky, Eugene A.
    MABS, 2015, 7 (03) : 584 - 604
  • [27] Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies
    Kevin A. Hay
    Cameron J. Turtle
    Drugs, 2017, 77 : 237 - 245
  • [28] CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies
    Qin, Hong
    Dong, Zhenyuan
    Wang, Xiuli
    Cheng, Wesley A.
    Wen, Feng
    Xue, Weili
    Sun, Han
    Walter, Miriam
    Wei, Guowei
    Smith, D. Lynne
    Sun, Xiuhua
    Fei, Fan
    Xie, Jianming
    Panagopoulou, Theano I.
    Chen, Chun-Wei
    Song, Joo Y.
    Aldoss, Ibrahim
    Kayembe, Clarisse
    Sarno, Luisa
    Muschen, Markus
    Inghirami, Giorgio G.
    Forman, Stephen J.
    Kwak, Larry W.
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (511)
  • [29] Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies
    Yang, Xingcheng
    Wei, Jia
    Zhou, Jianfeng
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 821 - 834
  • [30] Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma
    Tong, Chuan
    Zhang, Yajing
    Liu, Yang
    Ji, Xingyu
    Zhang, Wenying
    Guo, Yelei
    Han, Xiao
    Ti, Dongdong
    Dai, Hanren
    Wang, Chunmeng
    Yang, Qingming
    Liu, Wanli
    Wang, Yao
    Wu, Zhiqiang
    Han, Weidong
    BLOOD, 2020, 136 (14) : 1632 - 1644